Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
2025 · 1st Quarter (Jan 1 - Mar 31)
VERTEX PHARMACEUTICALS INCORPORATED
Filed by VERTEX PHARMACEUTICALS INCORPORATED.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2025
- Income
- Not reported
- Expenses
- $1,600,000.00
- Registrant
- VERTEX PHARMACEUTICALS INCORPORATED
- Filing UUID
- 82795878-d600-4129-ad81-67221d7675fa
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Issues related to corporate tax reform.
Education about non-opioid pain therapies and patient access to non-opioid medicines, education on alternative funding programs, education on the Million Veteran Program at the VA.
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Literal federal measure citations: S.864
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.